GRANT FABRY: Open Payments
NPI 1306527148 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,141 in 148 payments from 22 companies in 2025. Trend: 2023 $59 · 2024 $1,448 · 2025 $2,141
Food & beverage: $2,141
| Company | Payments | Amount |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 40 | $269 |
| Calliditas Therapeutics US Inc. | 7 | $206 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 15 | $204 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $187 |
| Travere Therapeutics, Inc. | 10 | $179 |
| Amgen Inc. | 12 | $155 |
| Vifor Pharma, Inc. | 11 | $150 |
| Otsuka America Pharmaceutical, Inc. | 8 | $148 |
| Novartis Pharmaceuticals Corporation | 8 | $129 |
| SCPHARMACEUTICALS INC. | 5 | $82 |
Products named: PURIFIED CORTROPHIN GEL, TARPEYO, JARDIANCE, Kerendia, TAVNEOS, Veltassa, JYNARQUE, Fabhalta.
Industry payments across NE — which companies pay providers there.
